RHYTHM BIOSCIENCES LIMITED — Investor Relations & Filings

Rhythm Biosciences Limited specializes in the development and commercialization of blood-based diagnostic technology for early cancer detection. The company’s primary product, ColoSTAT®, is a minimally invasive blood test designed to identify colorectal cancer by measuring specific protein biomarkers associated with the disease. ColoSTAT® is engineered to provide a reliable, cost-effective, and patient-friendly alternative to traditional screening methods, such as fecal immunochemical tests (FIT). The technology targets the global mass screening market, specifically addressing the needs of individuals who are non-compliant with current stool-based testing protocols. By facilitating higher screening participation rates, the company focuses on the early identification of colorectal cancer to improve clinical outcomes and survival rates through timely medical intervention.